$5.7 Billion KKR Buyout Takes Integer Private in Premium Deal — Integer Holdings Corporation

Event summary

KKR to acquire Integer Holdings for $5.7 billion in all-cash deal.
$127 per share represents a 51.8% premium over Integer’s April 29 closing price.
Transaction follows Integer’s board-led strategic review initiated April 30, 2026.
Deal expected to close by year-end, subject to regulatory and shareholder approvals.
Integer will become privately held, delisting from NYSE post-transaction.

The big picture

KKR’s acquisition of Integer underscores private equity’s appetite for scaling medical device manufacturing platforms amid rising demand for outsourced development. The $5.7 billion deal reflects a broader trend of strategic consolidation in the CDMO space, where scale and global footprint are increasingly critical differentiators. KKR’s track record suggests it will prioritize capacity expansion and technological innovation to solidify Integer’s position against competitors like West Pharmaceutical Services.

What we're watching

Strategic Alignment: Whether KKR’s long-term capital and healthcare expertise can accelerate Integer’s growth in competitive medical device markets.
Regulatory Hurdles: The pace at which regulatory approvals will clear, given the transaction’s scale and cross-border implications.
Employee Engagement: How KKR’s planned employee ownership program impacts Integer’s talent retention and operational continuity post-deal.